<DOC>
	<DOCNO>NCT00489593</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose drug Olanzapine give patient advanced cancer experience weight loss . Researchers want find Olanzapine help decrease weight loss patient experience cancer . How drug affect performance status , cancer-related symptom , nutritional status patient advance cancer also study .</brief_summary>
	<brief_title>Olanzapine Patients With Advanced Cancer Weight Loss</brief_title>
	<detailed_description>Olanzapine approve treatment schizophrenia bipolar disorder . However , patient receive drug reason also experience weight gain . Further study patient cancer show improvement appetite , decrease nausea , control flushing ( feel warmth ) sweating . If find eligible take part study receive first dose Olanzapine , routine blood test ( 2 teaspoon ) . You ask series question nutrition well able perform daily activity . These question take 20 minute answer . Your answer help study doctor decide study drug help gain weight weight gain help feel well . You also electrocardiogram ( ECG - test measure electrical activity heart ) . Women able child must negative blood pregnancy test ( 1 teaspoon ) . After test complete , begin receive Olanzapine . The study drug take mouth daily bedtime 28 day row . Seven different dos drug plan 6 patient enrolled level . The level assign depend enrol study . All participant begin take strength study drug . This gradually increase every 3 - 14 day reach high strength study drug dose level assign . About every 2 week study first month month thereafter , physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) , medical history discuss . You also routine blood test ( 2 teaspoon ) check general health . You continue receive high strength study drug dose level assign 4 month unless intolerable side effect weight continue decrease . The study doctor decide continue receive Olanzapine 4 month . This investigational study . The FDA approve Olanzapine mental health disease ( schizophrenia , acute mania , bipolar disorder ) . Its use prevent weight loss experimental . Up 57 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Patient confirm advanced cancer . 2 . Patients decrease daily caloric intake ( &lt; 1500 Calories/day ) , weight loss equivalent 10 % body weight six month 3 . Patients able oral intake dependant tube feeding , significant oropharyngeal obstruction , gastroduodenal obstruction , oral mucosal inflammation interfere oral intake . Patients undergone gastrojejunal bypass , esophagectomy , total gastrectomy exclude . 4 . ECOG performance status 2 less . 5 . Normal organ function : Creatinine le equal 2 time ULN ; Bilirubin le equal 2.5 time ULN 6 . Ability understand willingness sign write informed consent . 7 . Patients receive concurrent chemotherapy radiation therapy eligible enrollment . 8 . Expected life expectancy least 3 month . 1 . Uncontrolled concurrent illness unstable angina , myocardial infarction precede month , neutropenic fever , shock , symptomatic decompensate congestive heart failure , congestive Heart Failure NYHA III IV , active internal bleeding . 2 . Hypersensitivity olanzapine , history dyskinesia extrapyramidal syndrome atypical neuroleptic . 3 . Concurrent treatment atypical antipsychotic clozapine , risperidone , olanzapine , quetiapine , ziprasidone aripiprazole 4 . History clozapineinduced agranulocytosis patient increase risk neutropenia Olanzapine . 5 . Major surgery within four week study start day . 6 . Uncontrolled diabetes mellitus 7 . Uncontrolled seizure disorder ( episode previous 4 week ) . 8 . Pregnant Nursing woman . 9 . Patients may start appetite stimulant megace therapeutic dose steroid ( superior equal equivalent 4 mg dexamethasone/day ) , increase dose medication ( 50 % ) previous week .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Zyprexa</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Symbyax</keyword>
</DOC>